Medical imaging software publisher Medecom & start-up Hera-MI announce the signing of a 100% French partnership agreement for the distribution of the multimodality diagnostic Workstation associated with the innovative AI solution, to support the medical decision of radiologists in mammography & tomosynthesis.
A multimodality diagnostic workstation combined with AI decision support software for radiological diagnosis of breast cancer
Since 2000, Medecom has been an independent French software publisher, whose solutions cover all the needs of radiology centers or services. Medecom is already shining internationally. Hera-Mi, for its part, is the only French MedTech company to have developed AI decision support software for breast cancer screening based on negativation, applicable to 2D mammography and tomosynthesis. While this 2-in-1 solution optimizes workflow, it has also been designed to work with all mammography manufacturers.
With this agreement, the two companies offer Med Mammo, a unique diagnostic workstation for mammography and tomosynthesis. This post-processing software, independent of manufacturers, is available to all other modalities including MRI and CT scan. Many tools such as stitching and advanced measurements are also available for digital radiology. The innovation is based on the display protocols offered by Medecom and Breast-SlimView, a patented AI decision support software for breast cancer diagnosis, which can detect potentially suspicious areas, while automatically masking all physiologically non-pathological elements of the breast (vessels, connective tissues, mammary gland, muscles, etc.).
The two companies are delighted with the launch of this unique and 100% French diagnostic & AI station for the radiological diagnosis of breast cancer.
With 22 years of experience and expertise in the field of radiology and mammography, Medecom’s software solutions are present in more than 4500 facilities in 40 countries. They facilitate radiologists’ workflow in acquisition, diagnosis, archiving and communication.
Founded in Nantes in 2017, Hera-Mi is one of the 5 global MedTech startups to develop medical devices to help diagnose breast cancer through AI. It thus participates in the fight against cancer, which in the context of organized screening makes it possible to reduce mortality.